<DOC>
	<DOCNO>NCT02434484</DOCNO>
	<brief_summary>This PMS Symbenda Injection ( bendamustine hydrochloride ) Korean Patients . The main objective obtain safety information relate Symbenda treatment clinical practice .</brief_summary>
	<brief_title>Symbenda Post-Marketing Surveillance ( PMS )</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Subjects prescribe Symbenda per approve prescribe information Symbenda enrol study . This study conduct complete surveillance method ; subject meet inclusion/exclusion criterion administrate Symbenda first time conclusion agreement enrol . Patients meet follow criterion eligible inclusion study : 1 . Patients approve indication Symbenda Korea 2 . Patients verbal write consent use personal medical information study purpose Investigators refer approve indication contraindication regard inclusion criterion . Investigators refer approved indication contraindication regard exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Symbenda</keyword>
	<keyword>Non-Hodgkin 's lymphoma</keyword>
	<keyword>Chronic lymphocytic leukemia</keyword>
	<keyword>Multiple myeloma</keyword>
	<keyword>Bendamustine Hydrochloride</keyword>
</DOC>